Study sample | Registry sub-sample | |
---|---|---|
N = 3188 | N = 624 | |
Demographic characteristicsa | ||
Ageb [years; mean ± SD (median)] | 62.1 ± 12.7 [63.0] | 54.3 ± 11.6 [54.0] |
Geographic region [N (%)] | ||
West | 771 (24.2) | 165 (26.4) |
Northeast | 607 (19.0) | 151 (24.2) |
Southeast | 791 (24.8) | 117 (18.8) |
Central | 688 (21.6) | 103 (16.5) |
Other | 85 (2.7) | 51 (8.2) |
Unknown | 246 (7.7) | 37 (5.9) |
Trastuzumab initiation [N (%)] | ||
Trastuzumab initiated as neoadjuvant therapyc | 277 (8.7) | 50 (8.0) |
Trastuzumab initiated as adjuvant therapyd | 2911 (91.3) | 574 (92.0) |
Type of surgery prior to adjuvant trastuzumab [N (%)] | ||
Breast-removing | 1746 (54.8) | 367 (58.8) |
Breast-conserving | 1442 (45.2) | 257 (41.2) |
Radiation therapy prior to the first adjuvant trastuzumab [N (%)] | 1849 (58.0) | 427 (68.4) |
Comorbiditiese (>5 % prevalence) | ||
Charlson comorbidity index (Quan et al. 2005)f (mean ± SD [median]) | 4.2 ± 2.3 [3.0] | 3.7 ± 2.0 [3.0] |
Physical comorbidities (Elixhauser et al. 2004)g [N (%)] | ||
Valvular disease | 616 (19.3) | 65 (10.4) |
Peripheral vascular disorder | 203 (6.4) | 11 (1.8) |
Hypertension, uncomplicated | 1681 (52.7) | 233 (37.3) |
Hypertension, complicated | 218 (6.8) | 21 (3.4) |
Other neurological disorders | 184 (5.8) | 15 (2.4) |
Chronic pulmonary disease | 563 (17.7) | 65 (10.4) |
Diabetes without chronic complications | 595 (18.7) | 74 (11.9) |
Diabetes with chronic complications | 176 (5.5) | 17 (2.7) |
Hypothyroidism | 542 (17.0) | 75 (12.0) |
Rheumatoid arthritis/collagen vascular diseases | 166 (5.2) | 23 (3.7) |
Obesity | 371 (11.6) | 64 (10.3) |
Fluid and electrolyte disorders | 400 (12.5) | 74 (11.9) |
Deficiency anemia | 755 (23.7) | 147 (23.6) |
Psychoses | 163 (5.1) | 20 (3.2) |
Mental comorbidities (American Psychiatric Association 2013)h [N (%)] | ||
Depressive disorders | 502 (15.7) | 85 (13.6) |
Anxiety disorder | 437 (13.7) | 85 (13.6) |
Trauma- and stressor-related disorders | 135 (4.2) | 49 (7.9) |
Sleep-wake disorders | 390 (12.2) | 68 (10.9) |
Substance-related and addictive disorders | 348 (10.9) | 60 (9.6) |
Cancer characteristics (recorded in cancer registry) | ||
Breast cancer stagei [N (%)] | ||
Stage 0 | – | 1 (0.2) |
Stage I | – | 260 (41.7) |
Stage II | – | 268 (42.9) |
Stage III | – | 85 (13.6) |
Stage IV | – | 3 (0.5) |
Missing | – | 7 (1.1) |
Tumor size | ||
Mean size ± SD [median] (mm) | – | 28.5 ± 49.6 [20.0] |
Missing [N (%)] | – | 33 (5.3) |
Tumor type [N (%)] | – | |
Infiltrating duct carcinoma NOS—invasive | – | 454 (72.8) |
Infiltrating ductal carcinoma—invasive | – | 40 (6.4) |
Infiltrating duct carcinoma NOS | – | 18 (2.9) |
Infiltrating duct and lobular carcinoma—invasive | – | 30 (4.8) |
Inflammatory carcinoma—invasive | – | 11 (1.8) |
Lobular carcinoma NOS—invasive | – | 12 (1.9) |
Infiltrating duct mixed with other types—invasive | – | 10 (1.6) |
Carcinoma NOS—invasive | – | 8 (1.3) |
Other (<1 % each) | 41 (6.6) | |
Tumor histologic grade [N (%)] | – | |
Grade 1 | – | 30 (4.8) |
Grade 2 | – | 205 (32.9) |
Grade 3 | – | 330 (52.9) |
Grade 4 | – | 4 (0.6) |
Missing | – | 55 (8.8) |
Lymph node status [N (%)] | – | |
No regional lymph node involvement or isolated tumor cells | – | 324 (51.9) |
Some lymph node involvement | – | 272 (43.6) |
No regional lymph node involvement, but isolated tumor cells | – | 11 (1.8) |
Missing | – | 17 (2.7) |